Fenoterol Delivery by Respimat® Soft Mist Inhaler Versus CFC Metered Dose Inhaler: Cumulative Dose-Response Study in Asthma Patients

Journal of Asthma

Volumn 40, Issue 6, 2003, Pages 721-730

  Vincken, Walter ^a   Dewberry, Helen ^b   Moonen, Diane ^b  

^a UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^b University of Brussels ^*

Author keywords

Asthma; Bronchodilators; Chlorofluorocarbon compounds; Cumulative dosing; Fenoterol; Inhalation therapy; Metered dose inhaler; RESPIMAT soft mist inhaler

Indexed keywords

CHLOROFLUOROCARBON; FENOTEROL; FLUORINATED HYDROCARBON; PROPELLANT;

ADOLESCENT; ADULT; ARTICLE; ASTHMA; BLOOD SAMPLING; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEVICE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; METERED DOSE INHALER; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SOFT MIST INHALER; SPIROMETRY;

ADMINISTRATION, INHALATION; ADULT; AEROSOL PROPELLANTS; ASTHMA; BRONCHODILATOR AGENTS; CHLOROFLUOROCARBONS; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; EQUIPMENT DESIGN; FEMALE; FENOTEROL; HUMANS; MALE; METERED DOSE INHALERS; NEBULIZERS AND VAPORIZERS; RESPIRATORY FUNCTION TESTS; SAFETY; TIME FACTORS;

EID: 0142053855     PISSN: 02770903     EISSN: None     Source Type: Journal    
DOI: 10.1081/JAS-120023495     Document Type: Article

References (25)

1. Pavia D. Efficacy and safety of inhalation therapy in chronic obstructive pulmonary disease and asthma. Respirology 1997; 2(Suppl. 1): S5-S10.
2. Pavia D, McLeod L. The environmental impact of inhaled aerosols. Eur Respir Rev 1994; 4:75-77.
3. Wetterlin K. Turbuhaler: a new powder inhaler for administration of drugs to the airways. Pharm Res 1988; 5:506-508.
4. Brindley A, Sumby BS, Smith IJ, Prime D, Haywood PA, Grant A.C. Design, manufacture and dose consistency of the Serevent Diskus Inhaler. Pharm Tech Eur 1995; 7:14-22.
5. Partridge M, Woodcock A. Metered dose inhalers free of chlorofluorocarbons. Br Med J 1995; 310:684-685.
6. Zierenberg B, Eicher J, Dunne S, Freund B. Boehringer Ingelheim Nebulizer BINEB®: a new approach to inhalation therapy. In: Dalby RN, Byron PR, Farr SJ, eds. Respiratory drug delivery V: program and proceedings. Buffalo Grove, IL: Interpharm Press, 1996:187-193.
7. Zierenberg B. Optimizing the in vitro performance of Respimat. J Aerosol Med 1999; 12(Suppl. 1):S19-S24.
8. Ariyananda PL, Agnew JE, Clarke SW. Aerosol delivery systems for bronchial asthma. Postgrad Med J 1996; 72:151-156.
9. Matthys H. Inhalation delivery of asthma drugs. Lung 1990; 168(Suppl.):645-652.
10. Steed KP, Towse LJ, Freund B, Newman SP. Lung and oropharyngeal depositions of fenoterol hydrobromide delivered from the prototype III hand-held multidose Respimat® nebulizer. Eur J Pharm Sci 1997; 5:55-61.
11. Newman SP, Brown J, Steed K, Reader SJ, Kladders H. Lung deposition of fenoterol from Respimat®, a novel inhaler device for pulmonary drug delivery. J Aerosol Med 1997; 10:268.
12. Newman SP, Brown J, Steed KP, Reader SJ, Kladders H. Lung deposition of fenoterol and flunisolide delivered using a novel device for inhaled medicines. Comparison of Respimat with conventional metered-dose inhalers with and without spacer devices. Chest 1998; 113:957-963.
13. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis 1987; 136:225-244.
14. Quanjer PH, Tammeling GJ, Cotes JE, Pederson OF, Peslin R, Yernault J-C. Lung volumes and forced ventilatory flows. Report of Working Party Standardisation of Pulmonary Lung Function Tests. European Community for Steel and Coal. Eur Respir J 1993; 16:5-40.
15. Moss AJ. Prolonged QT-interval syndromes. J Am Med Assoc 1986; 256:2985-2987.
16. Committee on Proprietary Medicinal Products. Note For Guidance on Statistical Principles for Clinical Trials. London, 18 March 1998. CPMP/ICH/363/96.
17. Van Noord JA, Smeets JJ, Creemers JPHM, Greefhorst LPM, Dewberry H, Cornelissen PJG. Delivery of fenoterol via Respimat® a novel 'soft mist' inhaler. Respiration 2000; 67:672-678.
18. Iacono P, Velicitat P, Guemas E, Leclerc V, Thebault J-J. Improved delivery of ipratropium bromide using Respimat® (a new soft mist inhaler) compared with a conventional metered dose inhaler: cumulative dose response study in patients with COPD. Respir Med 2000; 94:490-495.
19. Kunkel G, Magnussen H, Bergmann K-C, Juergens UR, de Mey C, Freund E, Hinzmann R, Beckers B. Respimat® 9a new soft mist inhaler) delivering fenoterol plus ipratropium bromide provides equivalent bronchodilation at half the cumulative dose compared with a conventional metered dose inhaler in asthmatic patients. Respiration 2000; 67: 306-314.
20. Von Berg A, Jeena P.M, Soemantri P.A, Vertruyen A, Razzouk H, Schmidt P, Gerken F. Comparison of efficacy and safety of fenoterol/ipratropium (F/I) inhaled from a new propellant-free soft-mist inhaler or from a metered-dose inhaler (MDI) with spacer in paediatric patients with asthma. [abstract] Eur Respir J 2000; 16(Suppl. 31):384S.
21. National Institutes of Health. Global Initiative for Asthma. Global strategy for asthma management and prevention: NHLBI/WHO Workshop Report. National Institutes of Health, National Heart Lung and Blood Institute, 1995, Publication 95-3659.
22. Anonymous. Fenoterol in perspective. Auckland: ADIS Press, 1989, ISBN: 0-86471-026-7.
23. Musch W, Vincken W, Noppen M, Gorus F. Metabolic effects of inhaled fenoterol in normal subjects. Chest 1992; 102:1099-1103.
24. Dolovich M, Ruffin RE, Roberts R, Newhouse M.T. Optimal delivery of aerosols from metered dose inhalers. Chest 1981; 80(6 Suppl.):911-915.
25. Shenfield GM, Evans ME, Paterson JW. Absorption of drugs by the lung. Br J Clin Pharmacol 1976; 3:583-589.